Hello Rapid Response Subscriber,

This is week 6 of rapid response updates! As part of our effort to keep you in the loop, you’ll be getting an email update from us each week covering both emerging policy issues impacting industry and responsive AdvaMed activity.

Visit the Emerging Policy Response Center

Stay current on the latest updates, advocacy efforts, and resources to help navigate evolving policies. Encourage your colleagues to sign up for these weekly updates to stay informed and engaged!

If there are any issues, you'd like more information on—or emerging topics you'd like us to explore—please don’t hesitate to reach out.

Issue 1: US Court of International Trade Blocks Tariffs

What’s Happening:

Yesterday the U.S. International Court of International Trade (CIT) permanently blocked President Trump’s tariffs on key trading partners. The ruling held that the Executive Orders (EO) he used to implement tariffs are not authorized by IEEPA and that his use of the “reciprocal” duties went beyond the authority granted to him.

Why It Matters:

The ruling permanently blocked affected tariffs from going into effect, but appeals are already pending. The impacted tariffs are:

The 25 percent tariffs on goods from Mexico and Canada, which were imposed to address the fentanyl and illegal immigration issues.
The 20 percent tariff on goods from China, which was imposed to address the fentanyl issue.
The “reciprocal” tariffs, currently at 10 percent but scheduled to graduate to higher country-specific rates for approximately 60 countries and the EU, which were imposed to address balance of trade issues.

What’s Next & AdvaMed Action:

The Court has given the government 10 calendar days (until June 7th) to implement changes in duty collection. We are working to identify if tariffs need to continue being paid, and considerations for refunds, while this decision is under appeal. Additionally, all ongoing bilateral trade negotiations are likely to be impacted. AdvaMed is continuing to monitor this situation and will provide more information as it becomes available.

EMERGENCY WEBINAR TOMORROW: AdvaMed is hosting a members-only webinar tomorrow to provide more detail on the implications of this ruling for medtech.

Register Now

In Case You Missed It (Last Week's Recap)

1. Trade Policy Collaboration

Issue: AdvaMed and Swiss Medtech have jointly called on the U.S. and Swiss governments to pursue a “zero-for-zero” reciprocal tariff agreement for medical technologies and to formally recognize FDA approvals and clearances as part of regulatory alignment.
Why It Matters: Eliminating tariffs and reducing duplicative regulatory requirements would lower costs, streamline market access, and strengthen transatlantic MedTech supply chains.
What’s Next & AdvaMed Action: AdvaMed will continue advocating for these trade and regulatory priorities.

2. MAHA Commission Report on Childhood Chronic Disease

Issue: The MAHA Commission released its report addressing the rise of chronic disease in children.
Why it Matters: The report criticizes the food, chemical, and pharmaceutical industries for contributing to poor pediatric health outcomes.
AdvaMed Action: AdvaMed is continuing to review the report closely for implications to medtech.

Other RFIs/Comments We Are Tracking

To ensure alignment and efficiency, AdvaMed will continue to coordinate responses across teams and ensure consistency across related RFIs.

The Office of Management and Budget (OMB) has issued a Request for Information seeking public input on outdated, unnecessary, or burdensome federal regulations as part of a broader deregulatory initiative. This effort provides a platform for the MedTech industry to identify regulatory barriers that hinder innovation or patient care. AdvaMed has solicited member input across policy teams and divisions and has officially submitted comments. Access the submission here.
The U.S. Department of Health and Human Services (HHS), in coordination with the FDA, has issued a Request for Information (RFI) seeking public input on regulations that should be modified or eliminated across all HHS agencies. The initiative supports the administration’s 10-to-1 deregulatory policy and broader efforts to reduce regulatory burdens on providers and the healthcare system. The public comment portal is now open, and responses will be accepted for 60 days.
The Centers for Medicare & Medicaid Services (CMS) has issued a Request for Information on Medicare Regulatory Relief, inviting input on policies that may create unnecessary burdens or limit access to care. The comment deadline is June 10.